

IDEX CORP /DE/  
Form 10-Q  
October 31, 2011  
Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**  
For the quarterly period ended September 30, 2011

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**  
Commission file number 1-10235

**IDEX CORPORATION**

*(Exact Name of Registrant as Specified in its Charter)*

**Delaware**  
*(State or other jurisdiction of  
incorporation or organization)*

**36-3555336**  
*(I.R.S. Employer  
Identification No.)*

**1925 West Field Court, Lake Forest, Illinois**  
*(Address of principal executive offices)*

**60045**  
*(Zip Code)*

**Registrant's telephone number: (847) 498-7070**

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

## Edgar Filing: IDEX CORP /DE/ - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

Number of shares of common stock of IDEX Corporation outstanding as of October 26, 2011: 83,439,010.

**Table of Contents**

**TABLE OF CONTENTS**

**Part I. Financial Information**

|         |  |    |
|---------|--|----|
| Item 1. | <u>Financial Statements</u>  | 1  |
|         | <u>Condensed Consolidated Balance Sheets</u>   | 1  |
|         | <u>Condensed Consolidated Statements of Operations</u>                                       | 2  |
|         | <u>Condensed Consolidated Statements of Shareholders' Equity</u>                             | 3  |
|         | <u>Condensed Consolidated Statements of Cash Flows</u>                                       | 4  |
|         | <u>Notes to Condensed Consolidated Financial Statements</u>                                  | 5  |
| Item 2. | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 24 |
|         | <u>Cautionary Statement Under the Private Securities Litigation Reform Act</u>               | 24 |
|         | <u>Overview</u>  | 24 |
|         | <u>Results of Operations</u>   | 24 |
|         | <u>Liquidity and Capital Resources</u>   | 29 |
| Item 3. | <u>Quantitative and Qualitative Disclosures About Market Risk</u>                            | 32 |
| Item 4. | <u>Controls and Procedures</u>   | 32 |

**Part II. Other Information**

|         |  |    |
|---------|--|----|
| Item 1. | <u>Legal Proceedings</u>   | 32 |
| Item 2. | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 33 |
| Item 6. | <u>Exhibits</u>  | 33 |
|         | <u>Signatures</u>  | 34 |
|         | <u>Exhibit Index</u>   | 35 |

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements.****IDEX CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS****(in thousands except share and per share amounts)****(unaudited)**

|   | September 30, 2011 | December 31, 2010 |
|---|--------------------|-------------------|
| <b>ASSETS</b>   |                    |                   |
| Current assets  |                    |                   |
| Cash and cash equivalents   | \$ 220,461         | \$ 235,136        |
| Receivables, less allowance for doubtful accounts of \$5,728 at September 30, 2011 and \$5,322 at December 31, 2010 | 258,346            | 213,553           |
| Inventories net   | 271,617            | 196,546           |
| Other current assets  | 54,882             | 47,523            |
| Total current assets  | 805,306            | 692,758           |
| Property, plant and equipment net   | 219,702            | 188,562           |
| Goodwill  | 1,441,640          | 1,207,001         |
| Intangible assets net   | 393,947            | 281,392           |
| Other noncurrent assets   | 33,133             | 11,982            |
| Total assets  | \$ 2,893,728       | \$ 2,381,695      |
| <b>LIABILITIES AND SHAREHOLDERS EQUITY</b>  |                    |                   |
| Current liabilities   |                    |                   |
| Trade accounts payable  | \$ 119,738         | \$ 104,055        |
| Accrued expenses  | 173,854            | 117,879           |
| Current portion of long-term debt and short-term borrowings   | 85,395             | 119,445           |
| Dividends payable   | 14,172             | 12,289            |
| Total current liabilities   | 393,159            | 353,668           |
| Long-term borrowings  | 733,204            | 408,450           |
| Deferred income taxes   | 166,325            | 148,534           |
| Other noncurrent liabilities  | 95,619             | 95,383            |
| Total liabilities   | 1,388,307          | 1,006,035         |
| Commitments and contingencies   |                    |                   |
| Shareholders equity   |                    |                   |
| Preferred stock:  |                    |                   |
| Authorized: 5,000,000 shares, \$.01 per share par value; Issued: None   |                    |                   |
| Common stock:   |                    |                   |
| Authorized: 150,000,000 shares, \$.01 per share par value   |                    |                   |
| Issued: 85,897,983 shares at September 30, 2011 and 84,636,668 shares at December 31, 2010                          | 859                | 846               |
| Additional paid-in capital  | 485,673            | 441,271           |
| Retained earnings   | 1,109,168          | 1,005,040         |
|   | (64,626)           | (58,788)          |

Edgar Filing: IDEX CORP /DE/ - Form 10-Q

Treasury stock at cost: 2,730,385 shares at September 30, 2011 and 2,566,985 shares at December 31, 2010

|  |              |              |
|--|--------------|--------------|
| Accumulated other comprehensive loss       | (25,653)     | (12,709)     |
| Total shareholders' equity                 | 1,505,421    | 1,375,660    |
| Total liabilities and shareholders' equity | \$ 2,893,728 | \$ 2,381,695 |

See Notes to Condensed Consolidated Financial Statements.

**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(in thousands except per share amounts)

(unaudited)

|  | Three Months Ended |            | Nine Months Ended |              |
|--|--------------------|------------|-------------------|--------------|
|  | September 30,      |            | September 30,     |              |
|  | 2011               | 2010       | 2011              | 2010         |
| Net sales  | \$ 476,881         | \$ 373,731 | \$ 1,357,768      | \$ 1,107,855 |
| Cost of sales                                      | 295,349            | 219,598    | 812,697           | 651,360      |
| Gross profit                                       | 181,532            | 154,133    | 545,071           | 456,495      |
| Selling, general and administrative expenses       | 107,296            | 88,170     | 313,485           | 266,961      |
| Restructuring expenses                             | 2,931              | 3,524      | 2,931             | 6,422        |
| Operating income                                   | 71,305             | 62,439     | 228,655           | 183,112      |
| Other expense net                                  | 441                | 1,101      | 1,001             | 608          |
| Interest expense                                   | 7,763              | 4,162      | 20,937            | 11,195       |
| Income before income taxes                         | 63,101             | 57,176     | 206,717           | 171,309      |
| Provision for income taxes                         | 14,765             | 18,612     | 60,248            | 55,722       |
| Net income   | \$ 48,336          | \$ 38,564  | \$ 146,469        | \$ 115,587   |
| Basic earnings per common share                    | \$ 0.58            | \$ 0.47    | \$ 1.77           | \$ 1.42      |
| Diluted earnings per common share                  | \$ 0.58            | \$ 0.47    | \$ 1.75           | \$ 1.40      |
| <i>Share data:</i>                                 |                    |            |                   |              |
| Basic weighted average common shares outstanding   | 82,402             | 80,517     | 81,994            | 80,322       |
| Diluted weighted average common shares outstanding | 83,586             | 81,938     | 83,533            | 81,749       |

See Notes to Condensed Consolidated Financial Statements.

**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**

(in thousands except share amounts)

(unaudited)

|  | Common                               |                   | Accumulated Other Comprehensive Income |                                 |   | Treasury Stock | Total Shareholders' Equity |
|--|--------------------------------------|-------------------|--|---------------------------------|---|----------------|----------------------------|
|  | Stock and Additional Paid-In Capital | Retained Earnings | Cumulative Translation Adjustment      | Retirement Benefits Adjustments | Cumulative Unrealized Loss on Derivatives |                |                            |
| Balance, December 31, 2010   | \$ 442,117                           | \$ 1,005,040      | \$ 38,302                              | \$ (30,088)                     | \$ (20,923)                               | \$ (58,788)    | \$ 1,375,660               |
| Net income   |                                      | 146,469           |  |                                 |   |                | 146,469                    |
| Other comprehensive income, net of tax:  |                                      |                   |  |                                 |   |                |                            |
| Cumulative translation adjustment  |                                      |                   | 5,100                                  |                                 |   |                | 5,100                      |
| Amortization of retirement obligations   |                                      |                   |  | 2,354                           |   |                | 2,354                      |
| Net change on derivatives designated as cash flow hedges   |                                      |                   |  |                                 | (20,398)                                  |                | (20,398)                   |
| Other comprehensive income   |                                      |                   |  |                                 |   |                | (12,944)                   |
| Comprehensive income   |                                      |                   |  |                                 |   |                | 133,525                    |
| Issuance of 1,500,599 shares of common stock from issuance of unvested shares, exercise of stock options and deferred compensation plans, net of tax benefit | 35,217                               |                   |  |                                 |   |                | 35,217                     |
| Unvested shares surrendered for tax withholding  |                                      |                   |  |                                 |   | (5,838)        | (5,838)                    |
| Share-based compensation   | 9,198                                |                   |  |                                 |   |                | 9,198                      |
| Cash dividends declared \$ .51 per common share  |                                      | (42,341)          |  |                                 |   |                | (42,341)                   |
| Balance, September 30, 2011  | \$ 486,532                           | \$ 1,109,168      | \$ 43,402                              | \$ (27,734)                     | \$ (41,321)                               | \$ (64,626)    | \$ 1,505,421               |

See Notes to Condensed Consolidated Financial Statements.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(in thousands)****(unaudited)**

|   | <b>Nine Months<br/>Ended September 30,</b> |             |
|---|--|-------------|
|   | <b>2011</b>                                | <b>2010</b> |
| Cash flows from operating activities  |  |             |
| Net income  | \$ 146,469                                 | \$ 115,587  |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |             |
| Gain on sale of fixed assets  | (2,831)                                    |             |
| Depreciation and amortization   | 27,671                                     | 25,608      |
| Amortization of intangible assets   | 25,446                                     | 19,280      |
| Amortization of debt issuance expenses  | 947  | 371         |
| Share-based compensation expense  | 9,755                                      | 12,858      |
| Deferred income taxes   | 1,623                                      | 1,210       |
| Excess tax benefit from share-based compensation                                  | (4,920)                                    | (3,271)     |
| Changes in:   |  |             |
| Receivables   | (18,721)                                   | (19,684)    |
| Inventories   | (13,026)                                   | (27,664)    |
| Trade accounts payable  | (1,355)                                    | 14,698      |
| Accrued expenses  | 12,688                                     | 22,004      |
| Other net   | (8,137)                                    | (3,651)     |
| Net cash flows provided by operating activities                                   | 175,609                                    | 157,346     |
| Cash flows from investing activities  |  |             |
| Cash purchases of property, plant and equipment                                   | (27,984)                                   | (26,006)    |
| Proceeds from disposal of fixed assets  | 12,651                                     |             |
| Acquisition of businesses, net of cash acquired                                   | (446,069)                                  | (68,330)    |
| Other net   | (2,262)                                    |             |
| Net cash flows used in investing activities                                       | (463,664)                                  | (94,336)    |
| Cash flows from financing activities  |  |             |
| Borrowings under credit facilities for acquisitions                               | 365,000                                    | 53,866      |
| Borrowings under revolving facilities   | 381,222                                    |             |
| Borrowings under credit facilities  | 1,883                                      | 7,896       |
| Proceeds from issuance of 2.58% Senior Euro Notes                                 |  | 96,762      |
| Payments under revolving facilities, credit facilities and term loan              | (462,944)                                  | (73,377)    |
| Debt issuance costs   | (2,433)                                    |             |
| Dividends paid  | (40,458)                                   | (34,082)    |
| Proceeds from stock option exercises  | 31,333                                     | 8,725       |
| Excess tax benefit from share-based compensation                                  | 4,920                                      | 3,271       |
| Unvested shares surrendered for tax withholding                                   | (5,838)                                    | (743)       |
| Net cash flows provided by financing activities                                   | 272,685                                    | 62,318      |
| Effect of exchange rate changes on cash and cash equivalents                      | 695  | 7,200       |
| Net increase (decrease) in cash   | (14,675)                                   | 132,528     |
| Cash and cash equivalents at beginning of year                                    | 235,136                                    | 73,526      |



Edgar Filing: IDEX CORP /DE/ - Form 10-Q

|  |            |            |
|--|------------|------------|
| Cash and cash equivalents at end of period | \$ 220,461 | \$ 206,054 |
| <b>Supplemental cash flow information</b>  |            |            |
| Cash paid for:                             |            |            |
| Interest                                   | \$ 16,246  | \$ 10,118  |
| Income taxes                               | 46,749     | 46,347     |
| Significant non-cash activities:           |            |            |
| Contingent consideration for acquisition   | 2,707      |            |
| Debt acquired with acquisition of business | 1,400      | 722        |
| Issuance of unvested shares                | 12,089     | 2,917      |

See Notes to Condensed Consolidated Financial Statements.

---

**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(unaudited)**

**1. Basis of Presentation and Significant Accounting Policies**

The Condensed Consolidated Financial Statements of IDEX Corporation ( IDEX or the Company ) have been prepared in accordance with the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, that the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the three and nine months ended September 30, 2011 are not necessarily indicative of the results to be expected for the entire year.

The condensed consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

***Adoption of New Accounting Standards***

In October 2009, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) No. 2009-13, Revenue Recognition (Topic 605) Multiple-Deliverable Revenue Arrangements. ASU No. 2009-13 addresses the accounting for multiple-deliverable arrangements to enable vendors to account for products or services (deliverables) separately rather than as a combined unit. This guidance establishes a selling price hierarchy for determining the selling price of a deliverable, which is based on: (a) vendor-specific objective evidence; (b) third-party evidence; or (c) estimated selling price. This guidance also eliminates the residual method of allocation and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables using the relative selling price method. ASU No. 2009-13 is effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. The Company's adoption of ASU No. 2009-13 effective January 1, 2011 did not have a material impact on its consolidated financial position, results of operations or cash flows.

In December 2010, the FASB issued ASU No. 2010-29, Business Combinations (Topic 805), Disclosure of Supplementary Pro Forma Information for Business Combinations. ASU No. 2010-29 requires revenues and earnings of the combined entity be disclosed as if the business combination occurred as of the beginning of the comparable prior annual reporting period. This ASU also requires additional disclosures about adjustments included in the reported pro forma revenues and earnings. The Company adopted the provisions of ASU No. 2010-29 prospectively for business combinations for which the acquisition date is on or after January 1, 2011.

***New Accounting Pronouncements***

In May 2011, the FASB issued ASU 2011-04, which is an update to Topic 820, Fair Value Measurement. This update establishes common requirements for measuring fair value and related disclosures in accordance with accounting principles generally accepted in the United States and international financial reporting standards. This amendment did not require additional fair value measurements. ASU 2011-04 is effective for all interim and annual reporting periods beginning after December 15, 2011. ASU 2011-04 is not expected to have a material impact on the consolidated financial position, results of operations or cash flows of the Company.

In June 2011, the FASB issued ASU 2011-05, an update to Topic 220, Comprehensive Income. This update eliminates the option of presenting the components of other comprehensive income as part of the statement of changes in stockholders' equity, requires consecutive presentation of the statement of net income and other comprehensive income and requires reclassification adjustments from other comprehensive income to net income to be shown on the financial statements. ASU 2011-05 is effective for all interim and annual reporting periods beginning after December 15, 2011. ASU 2011-05 is not expected to have a material impact on the consolidated financial position, results of operations or cash flows of the Company.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

In September 2011, the FASB issued ASU 2011-08 which provides an entity the option to first assess qualitative factors to determine whether it is necessary to perform the current two-step test for goodwill impairment. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test is required. Otherwise, no further testing is required. The revised standard is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. However, an entity can choose to adopt earlier even if its annual test date is before the issuance of the final standard, provided that the entity has not yet performed its 2011 annual impairment test or issued its financial statements. As of September 30, 2011, the Company did not elect to early adopt ASU 2011-08; however, the Company may elect to early adopt prior to its annual test date. ASU 2011-08 is not expected to have a material impact on the consolidated financial position, results of operations or cash flows of the Company.

In September 2011, the FASB issued ASU 2011-09 which requires enhanced disclosures around an employer's participation in multiemployer pension plans. The standard is intended to provide more information about an employer's financial obligations to a multiemployer pension plan to help financial statement users better understand the financial health of the significant plans in which the employer participates. ASU 2011-09 is not expected to have a material impact on the consolidated financial position, results of operations or cash flows of the Company.

**2. Restructuring**

The Company entered into a restructuring initiative in the third quarter of 2011. This initiative supports the implementation of key strategic efforts designed to facilitate long-term sustainable growth through cost reduction actions, primarily consisting of employee reductions and facility rationalization. We record accruals for employee termination benefits related to employee reductions based on the guidance of ASC 420 Exit or Disposal Cost Obligations. The costs incurred related to these initiatives are included in Restructuring expenses in the Consolidated Statements of Operations while the restructuring accruals are included in Accrued expenses in our Consolidated Balance Sheets.

During the three and nine months ended September 30, 2011, the Company recorded \$2.9 million of pre-tax restructuring expenses related to the 2011 restructuring initiative for employee severance related to employee reductions across various functional areas as well as facility rationalization. The 2011 restructuring initiative included severance benefits for over 100 employees.

During the three and nine months ended September 30, 2010, the Company recorded \$3.5 million and \$6.4 million, respectively, of pre-tax restructuring expenses related to its 2009 restructuring initiative.

Pre-tax restructuring expenses, by segment, for the three and nine months ended September 30, 2011 were as follows:

|                                    | Severance<br>Costs | Exit Costs<br>(in thousands) | Total    |
|------------------------------------|--------------------|------------------------------|----------|
| Fluid & Metering Technologies      | \$ 528             | \$ 51                        | \$ 579   |
| Health & Science Technologies      | 407                | 21                           | 428      |
| Dispensing Equipment               | 1,225              | 87                           | 1,312    |
| Fire & Safety/Diversified Products | 390                |                              | 390      |
| Corporate office and other         | 222                |                              | 222      |
| Total restructuring costs          | \$ 2,768           | \$ 163                       | \$ 2,931 |



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

Pre-tax restructuring expenses, by segment, for the three and nine months ended September 30, 2010 were as follows:

|                                    | Three Months             |               |          | Nine Months              |               |          |
|------------------------------------|--------------------------|---------------|----------|--------------------------|---------------|----------|
|                                    | Ended September 30, 2010 |               |          | Ended September 30, 2010 |               |          |
|                                    | Severance<br>Costs       | Exit<br>Costs | Total    | Severance<br>Costs       | Exit<br>Costs | Total    |
|                                    | (in thousands)           |               |          |                          |               |          |
| Fluid & Metering Technologies      | \$ 1,153                 | \$            | \$ 1,153 | \$ 1,864                 | \$ 202        | \$ 2,066 |
| Health & Science Technologies      | 2,102                    | 269           | 2,371    | 2,948                    | 323           | 3,271    |
| Dispensing Equipment               |                          |               |          | 120                      |               | 120      |
| Fire & Safety/Diversified Products |                          |               |          | 477                      |               | 477      |
| Corporate office and other         |                          |               |          | 396                      | 92            | 488      |
| Total restructuring costs          | \$ 3,255                 | \$ 269        | \$ 3,524 | \$ 5,805                 | \$ 617        | \$ 6,422 |

Restructuring accruals of \$2.2 million and \$3.5 million as of September 30, 2011 and December 31, 2010, respectively, are reflected in Accrued expenses in the Consolidated Balance Sheets as follows:

|                               | (In thousands) |
|-------------------------------|----------------|
| Balance at January 1, 2011    | \$ 3,543       |
| Restructuring costs           | 2,931          |
| Payments/Utilization          | (4,307)        |
| Balance at September 30, 2011 | \$ 2,167       |

**3. Acquisitions**

On January 20, 2011, the Company acquired the membership interests of Advanced Thin Films, LLC ( AT Films ). AT Films specializes in optical components and coatings for applications in the fields of scientific research, defense, aerospace, telecommunications and electronics manufacturing. AT Films core competence is the design and manufacture of filters, splitters, reflectors and mirrors with the precise physical properties required to support their customers most challenging and cutting-edge optical applications. Headquartered in Boulder, Colorado, AT Films has annual revenues of approximately \$9.0 million. AT Films operates within the Health & Science Technologies Segment as a part of the IDEX optics and photonics platform. The Company acquired AT Films for an aggregate purchase price of \$34.5 million, consisting of \$31.8 million in cash and contingent consideration valued at approximately \$2.7 million. The potential undiscounted amount of all future payments that the Company could be required to pay under the contingent consideration arrangement is between \$0 and \$3.0 million. Goodwill and intangible assets recognized as part of this transaction were \$16.7 million and \$11.4 million, respectively. The \$16.7 million of goodwill is deductible for tax purposes.

On March 11, 2011, the Company completed the acquisition of Microfluidics International Corporation ( Microfluidics ). Microfluidics is a global leader in the design and manufacture of laboratory and commercial equipment used in the production of micro and nano scale materials for the pharmaceutical and chemical markets. Microfluidics is the exclusive producer of the Microfluidizer® family of high shear fluid processors for uniform particle size reduction, robust cell disruption and nanoparticle creation. Microfluidics operates within the Health & Science Technologies Segment as a part of the IDEX Pharma platform. The Company acquired Microfluidics for an aggregate purchase price of

## Edgar Filing: IDEX CORP /DE/ - Form 10-Q

\$18.5 million in cash. Headquartered in Newton, Massachusetts, Microfluidics has annual revenues of approximately \$16.0 million. Goodwill and intangible assets recognized as part of this transaction were \$4.3 million and \$9.7 million, respectively. The \$4.3 million of goodwill is not deductible for tax purposes.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

On June 10, 2011, the Company completed the acquisition of CVI Melles Griot ( CVI MG ). CVI MG is a global leader in the design and manufacture of precision photonic solutions used in the life sciences, research, semiconductor, security and defense markets. CVI MG s innovative products are focused on the generation, control and productive use of light for a variety of key science and industrial applications. Products include specialty lasers and light sources, electro-optical components, specialty shutters, opto-mechanical assemblies and components. In addition, CVI MG produces critical components for life science research, electronics manufacturing, military and other industrial applications including lenses, mirrors, filters and polarizers. These components are utilized in a number of important applications such as spectroscopy, cytometry (cell counting), guidance systems for target designation, remote sensing, metrology and optical lithography. CVI MG operates within the Health and Science Technologies Segment as part of the IDEX optics and photonics platform. The Company acquired CVI MG for an aggregate purchase price of \$397.1 million, consisting of \$395.7 million in cash and the assumption of approximately \$1.4 million of debt. Approximately \$365.0 million of the cash payment was financed with borrowings under the Company s revolving credit facility. Headquartered in Albuquerque, New Mexico, with manufacturing sites located on three continents, CVI MG has annual revenues of approximately \$185.0 million. Goodwill and intangible assets recognized as part of this transaction were \$206.9 million and \$115.8 million, respectively. Approximately \$106.6 million of goodwill is deductible for tax purposes.

The purchase price for CVI MG, AT Films and Microfluidics has been allocated to the assets acquired and liabilities assumed based on estimated fair values at the date of the acquisition. The Company is in the process of finalizing appraisals of tangible and intangible assets and it is continuing to evaluate the initial purchase price allocations, as of the acquisition date, which will be adjusted as additional information relative to the fair values of the assets and liabilities of the businesses become known. Accordingly, management has used its best estimate in the initial purchase price allocation as of the date of the filing of these financial statements.

The allocation of the acquisition costs to the assets acquired and liabilities assumed, based on their estimated fair values, is as follows:

|  | AT<br>Films      | Microfluidics    | CVI MG            | Total             |
|--|------------------|------------------|-------------------|-------------------|
|  | (In thousands)   |                  |                   |                   |
| Accounts receivable                        | \$ 947           | \$ 1,760         | \$ 24,065         | \$ 26,772         |
| Inventory                                  | 852              | 2,226            | 57,986            | 61,064            |
| Other current assets, net of cash acquired | 73               | 1,087            | 5,866             | 7,026             |
| Property, plant and equipment              | 5,019            | 567              | 32,250            | 37,836            |
| Goodwill                                   | 16,688           | 4,305            | 206,883           | 227,876           |
| Intangible assets                          | 11,435           | 9,717            | 115,777           | 136,929           |
| Other assets                               | 24               | 1,915            | 2,118             | 4,057             |
| <b>Total assets acquired</b>               | <b>35,038</b>    | <b>21,577</b>    | <b>444,945</b>    | <b>501,560</b>    |
| <b>Total liabilities assumed</b>           | <b>(527)</b>     | <b>(3,043)</b>   | <b>(49,194)</b>   | <b>(52,764)</b>   |
| <b>Net assets acquired</b>                 | <b>\$ 34,511</b> | <b>\$ 18,534</b> | <b>\$ 395,751</b> | <b>\$ 448,796</b> |

Of the \$136.9 million of acquired intangible assets, \$47.0 million was assigned to the CVI MG trade name and is not subject to amortization. The remaining \$89.9 million of acquired intangible assets consist of patents, trade names, customer relationships, non-compete and unpatented technology, which are being amortized over a life of 2-15 years. The goodwill recorded for the acquisitions reflects the strategic fit and revenue and earnings growth potential of these businesses.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

The Company incurred \$5.6 million of acquisition-related transaction costs in the first nine months of 2011. These costs were recorded in selling, general and administrative expense and were related to completed transactions, pending transactions and potential transactions, including certain transactions that ultimately were not completed.

In accordance with ASU 2010-29, Disclosure of Supplementary Pro Forma Information for Business Combinations, the following unaudited pro forma information illustrates the effect on the Company's net sales and net income for the three and nine months ended September 30, 2011 and 2010, assuming that the 2011 acquisitions had taken place at the beginning of 2010. The pro forma net income reflects adjustments for the three and nine months ended September 30, 2010 to include \$0 and \$16.4 million, respectively of pre-tax acquisition fair value inventory charges. The pro forma net income reflects adjustments for the three and nine months ended September 30, 2011 to exclude \$12.8 million and \$24.0 million, respectively of pre-tax acquisition-related costs and fair value inventory charges. The 2011 and 2010 supplemental pro forma net income are also adjusted to reflect the comparable impact of additional depreciation and amortization expense resulting from the fair value measurement of tangible and intangible assets and financing costs relating to the 2011 acquisitions.

|                            | <b>Three Months</b>        |             | <b>Nine Months</b>         |              |
|----------------------------|----------------------------|-------------|----------------------------|--------------|
|                            | <b>Ended September 30,</b> |             | <b>Ended September 30,</b> |              |
|                            | <b>2011</b>                | <b>2010</b> | <b>2011</b>                | <b>2010</b>  |
|                            | <b>(In thousands)</b>      |             |                            |              |
| Net sales                  | \$ 476,881                 | \$ 421,651  | \$ 1,440,832               | \$ 1,249,177 |
| Net income                 | 58,141                     | 39,398      | 157,556                    | 105,803      |
| Diluted earnings per share | \$ 0.70                    | \$ 0.48     | \$ 1.89                    | \$ 1.29      |

These pro forma results do not purport to be indicative of the results of operations that would have resulted had the acquisitions occurred on the date indicated or that may result in the future.

**4. Business Segments**

The Company has four reportable business segments: Fluid & Metering Technologies, Health & Science Technologies, Dispensing Equipment and Fire & Safety/Diversified Products.

The Fluid & Metering Technologies Segment designs, produces and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems and provides flow monitoring and other services for water and wastewater. The Health & Science Technologies Segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets, and precision gear and peristaltic pump technologies that meet exacting OEM specifications. The Dispensing Equipment Segment produces precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses. The Fire & Safety/Diversified Products Segment produces firefighting pumps and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, and engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications.



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

Information on the Company's business segments is presented below, based on the nature of products and services offered. The Company evaluates performance based on several factors, of which operating income is the primary financial measure. Intersegment sales are accounted for at fair value as if the sales were to third parties. Certain prior year amounts have been revised to reflect the movement of the Pharma group from the Fluid & Metering Technologies Segment to the Health & Science Technologies Segment.

|                                     | <b>Three Months</b>   |                   | <b>Nine Months</b>   |                     |
|-------------------------------------|-----------------------|-------------------|----------------------|---------------------|
|                                     | <b>Ended</b>          |                   | <b>Ended</b>         |                     |
|                                     | <b>September 30,</b>  |                   | <b>September 30,</b> |                     |
|                                     | <b>2011</b>           | <b>2010</b>       | <b>2011</b>          | <b>2010</b>         |
|                                     | <b>(In thousands)</b> |                   |                      |                     |
| <i>Net sales</i>                    |                       |                   |                      |                     |
| Fluid & Metering Technologies:      |                       |                   |                      |                     |
| External customers                  | \$ 201,821            | \$ 169,574        | \$ 602,109           | \$ 505,128          |
| Intersegment sales                  | 123                   | 196               | 359                  | 553                 |
| <b>Total group sales</b>            | <b>201,944</b>        | <b>169,770</b>    | <b>602,468</b>       | <b>505,681</b>      |
| Health & Science Technologies:      |                       |                   |                      |                     |
| External customers                  | 176,501               | 110,856           | 453,534              | 307,493             |
| Intersegment sales                  | 263                   | 574               | 984                  | 3,459               |
| <b>Total group sales</b>            | <b>176,764</b>        | <b>111,430</b>    | <b>454,518</b>       | <b>310,952</b>      |
| Dispensing Equipment:               |                       |                   |                      |                     |
| External customers                  | 25,092                | 26,352            | 93,079               | 100,992             |
| Intersegment sales                  | 51                    | 128               | 368                  | 177                 |
| <b>Total group sales</b>            | <b>25,143</b>         | <b>26,480</b>     | <b>93,447</b>        | <b>101,169</b>      |
| Fire & Safety/Diversified Products: |                       |                   |                      |                     |
| External customers                  | 73,467                | 66,949            | 209,046              | 194,242             |
| Intersegment sales                  | 125                   | 44                | 321                  | 143                 |
| <b>Total group sales</b>            | <b>73,592</b>         | <b>66,993</b>     | <b>209,367</b>       | <b>194,385</b>      |
| Intersegment elimination            | (562)                 | (942)             | (2,032)              | (4,332)             |
| <b>Total net sales</b>              | <b>\$ 476,881</b>     | <b>\$ 373,731</b> | <b>\$ 1,357,768</b>  | <b>\$ 1,107,855</b> |
| <i>Operating income</i>             |                       |                   |                      |                     |
| Fluid & Metering Technologies       | \$ 39,519             | \$ 29,941         | \$ 120,044           | \$ 90,391           |
| Health & Science Technologies       | 20,651                | 23,274            | 79,830               | 64,186              |
| Dispensing Equipment                | 946                   | 2,711             | 16,962               | 19,062              |
| Fire & Safety/Diversified Products  | 18,317                | 17,045            | 50,308               | 44,032              |

Edgar Filing: IDEX CORP /DE/ - Form 10-Q

|                            |           |           |            |            |
|----------------------------|-----------|-----------|------------|------------|
| Corporate office and other | (8,128)   | (10,532)  | (38,489)   | (34,559)   |
| Total operating income     | 71,305    | 62,439    | 228,655    | 183,112    |
| Interest expense           | 7,763     | 4,162     | 20,937     | 11,195     |
| Other expense-net          | (441)     | (1,101)   | (1,001)    | (608)      |
| Income before taxes        | \$ 63,101 | \$ 57,176 | \$ 206,717 | \$ 171,309 |

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

|   | September 30,<br>2011 | December 31,<br>2010 |
|---|-----------------------|----------------------|
|   | (In thousands)        |                      |
| <i>Assets:</i>                            |                       |                      |
| Fluid & Metering Technologies             | \$ 1,069,132          | \$ 1,040,601         |
| Health & Science Technologies             | 1,216,982             | 718,884              |
| Dispensing Equipment                      | 244,220               | 205,540              |
| Fire & Safety/Diversified Products        | 292,919               | 278,567              |
| Corporate office and other <sup>(1)</sup> | 70,475                | 138,103              |
| <b>Total assets</b>                       | <b>\$ 2,893,728</b>   | <b>\$ 2,381,695</b>  |

(1) Includes intersegment eliminations.

**5. Earnings Per Common Share**

Earnings per common share ( EPS ) are computed by dividing net income by the weighted average number of shares of common stock (basic) plus common stock equivalents outstanding (diluted) during the period. Common stock equivalents consist of stock options, which have been included in the calculation of weighted average shares outstanding using the treasury stock method, unvested shares, and shares issuable in connection with certain deferred compensation agreements ( DCUs ).

ASC 260 Earnings Per Share , concludes that all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding unvested shares are participating securities. Accordingly, earnings per common share are computed using the two-class method prescribed by ASC 260. Net income attributable to common shareholders was reduced by \$0.3 million for both the three months ended September 30, 2011 and 2010. Net income attributable to common shareholders was reduced by \$1.0 million for both the nine months ended September 30, 2011 and 2010.

Basic weighted average shares reconciles to diluted weighted average shares as follows:

|   | Three Months<br>Ended September 30, |               | Nine Months<br>Ended September 30, |               |
|---|-------------------------------------|---------------|------------------------------------|---------------|
|   | 2011                                | 2010          | 2011                               | 2010          |
|   | (In thousands)                      |               |                                    |               |
| Basic weighted average common shares outstanding            | 82,402                              | 80,517        | 81,994                             | 80,322        |
| Dilutive effect of stock options, unvested shares, and DCUs | 1,184                               | 1,421         | 1,539                              | 1,427         |
| <b>Diluted weighted average common shares outstanding</b>   | <b>83,586</b>                       | <b>81,938</b> | <b>83,533</b>                      | <b>81,749</b> |

Options to purchase approximately 0.2 million and 0.5 million shares of common stock for the three months ended September 30, 2011 and 2010, respectively and options to purchase approximately 0.9 million and 2.9 million shares of common stock for the nine months ended

## Edgar Filing: IDEX CORP /DE/ - Form 10-Q

September 30, 2011 and 2010, respectively, were not included in the computation of diluted EPS because the exercise price was greater than the average market price of the Company's common stock and, therefore, the effect of their inclusion would be antidilutive.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)****6. Inventories**

The components of inventories as of September 30, 2011 and December 31, 2010 were:

|                                   | September 30,<br>2011 | December 31,<br>2010 |
|-----------------------------------|-----------------------|----------------------|
|                                   | (In thousands)        |                      |
| Raw materials and component parts | \$ 163,329            | \$ 126,901           |
| Work-in-process                   | 44,319                | 23,164               |
| Finished goods                    | 63,969                | 46,481               |
| Total                             | \$ 271,617            | \$ 196,546           |

Inventories are stated at the lower of cost or market. Cost, which includes material, labor, and factory overhead, is determined on a FIFO basis.

**7. Goodwill and Intangible Assets**

The changes in the carrying amount of goodwill for the nine months ended September 30, 2011, by reportable business segment, were as follows:

|   | Fluid &<br>Metering<br>Technologies | Health &<br>Science<br>Technologies | Dispensing<br>Equipment<br>(In thousands) | Fire &<br>Safety/<br>Diversified<br>Products | Total        |
|---|-------------------------------------|-------------------------------------|---|--|--------------|
| Balance at December 31, 2010 <sup>(1)</sup> | \$ 523,766                          | \$ 439,415                          | \$ 98,780                                 | \$ 145,040                                   | \$ 1,207,001 |
| Acquisition adjustments                     |                                     | 286                                 |   |  | 286          |
| Foreign currency translation                | 2,914                               | 43                                  | 1,978                                     | 1,542  | 6,477        |
| Acquisitions                                |                                     | 227,876                             |   |  | 227,876      |
| Balance at September 30, 2011               | \$ 526,680                          | \$ 667,620                          | \$ 100,758                                | \$ 146,582                                   | \$ 1,441,640 |

(1) Revised to reflect the movement of the Pharma group from the Fluid & Metering Technologies Segment to the Health & Science Technologies Segment.

ASC 350 Goodwill and Other Intangible Assets requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. Annually on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. The Company concluded that the fair value of each of the reporting units was in excess of the carrying value as of October 31, 2010. The Company did not consider there to be any triggering event that would require an interim impairment assessment, therefore none of the goodwill or other acquired intangible assets with indefinite lives were tested for impairment during the nine months ended September 30, 2011.



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at September 30, 2011 and December 31, 2010:

|                                   | At September 30, 2011       |                             |            | Weighted<br>Average<br>Life<br>(In thousands) | At December 31, 2010        |                             |            |
|-----------------------------------|-----------------------------|-----------------------------|------------|---|-----------------------------|-----------------------------|------------|
|                                   | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization | Net        |   | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization | Net        |
| Amortized intangible assets:      |                             |                             |            |   |                             |                             |            |
| Patents                           | \$ 11,360                   | \$ (4,090)                  | \$ 7,270   | 12  | \$ 9,906                    | \$ (5,052)                  | \$ 4,854   |
| Trade names                       | 73,530                      | (17,248)                    | 56,282     | 14  | 69,043                      | (13,769)                    | 55,274     |
| Customer relationships            | 223,608                     | (63,829)                    | 159,780    | 10  | 169,065                     | (47,686)                    | 121,379    |
| Non-compete agreements            | 4,809                       | (3,874)                     | 935        | 4   | 4,087                       | (3,501)                     | 586        |
| Unpatented technology             | 71,422                      | (13,799)                    | 57,622     | 11  | 43,206                      | (9,407)                     | 33,799     |
| Other                             | 5,957                       | (3,007)                     | 2,950      | 10  | 5,957                       | (2,557)                     | 3,400      |
| Total amortized intangible assets | 390,686                     | (105,847)                   | 284,839    |   | 301,264                     | (81,972)                    | 219,292    |
| Unamortized intangible assets:    |                             |                             |            |   |                             |                             |            |
| Banjo trade name                  | 62,100                      |                             | 62,100     |   | 62,100                      |                             | 62,100     |
| CVI Melles Griot trade name       | 47,008                      |                             | 47,008     |   |                             |                             |            |
| Total intangible assets           | \$ 499,794                  | \$ (105,847)                | \$ 393,947 |   | \$ 363,364                  | \$ (81,972)                 | \$ 281,392 |

The unamortized trade names are indefinite lived intangible assets which are tested for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the asset might be impaired.

**8. Accrued Expenses**

The components of accrued expenses as of September 30, 2011 and December 31, 2010 were:

|                                       | September 30, December 31,<br>2011 2010<br>(In thousands) |           |
|---------------------------------------|---|-----------|
| Payroll and related items             | \$ 59,077   | \$ 46,937 |
| Management incentive compensation     | 14,739  | 19,985    |
| Income taxes payable                  | 10,341  | 6,126     |
| Deferred income taxes                 | 319   | 723       |
| Insurance                             | 5,379   | 5,544     |
| Warranty                              | 4,690   | 3,831     |
| Deferred revenue                      | 9,816   | 7,172     |
| Restructuring                         | 2,167   | 3,543     |
| Interest rate exchange agreements     | 36,840  | 2,328     |
| Liability for uncertain tax positions | 1,484   | 1,647     |

Edgar Filing: IDEX CORP /DE/ - Form 10-Q

|  |            |            |
|--|------------|------------|
| Accrued interest                         | 4,845      | 1,101      |
| Contingent consideration for acquisition | 1,394      |            |
| Other                                    | 22,763     | 18,942     |
| Total accrued expenses                   | \$ 173,854 | \$ 117,879 |



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)****9. Other Noncurrent Liabilities**

The components of noncurrent liabilities as of September 30, 2011 and December 31, 2010 were:

|   | <b>September 30, December 31,</b> |                  |
|---|-----------------------------------|------------------|
|   | <b>2011</b>                       | <b>2010</b>      |
|   | <b>(In thousands)</b>             |                  |
| Pension and retiree medical obligations   | \$ 76,839                         | \$ 74,559        |
| Liability for uncertain tax positions     | 4,359                             | 5,912            |
| Deferred revenue                          | 3,321                             | 4,225            |
| Other                                     | 11,100                            | 10,687           |
| <b>Total other noncurrent liabilities</b> | <b>\$ 95,619</b>                  | <b>\$ 95,383</b> |

**10. Borrowings**

Borrowings at September 30, 2011 and December 31, 2010 consisted of the following:

|                                   | <b>September 30, December 31,</b> |                   |
|-----------------------------------|-----------------------------------|-------------------|
|                                   | <b>2011</b>                       | <b>2010</b>       |
|                                   | <b>(In thousands)</b>             |                   |
| Revolving Facility                | \$ 320,938                        | \$ 27,842         |
| Credit Facility                   |                                   | 27,842            |
| Term Loan                         | 82,000                            | 90,000            |
| 2.58% Senior Euro Notes           | 110,134                           | 107,341           |
| 4.5% Senior Notes                 | 298,523                           | 298,427           |
| Other borrowings                  | 7,004                             | 4,285             |
| <b>Total borrowings</b>           | <b>818,599</b>                    | <b>527,895</b>    |
| Less current portion              | 85,395                            | 119,445           |
| <b>Total long-term borrowings</b> | <b>\$ 733,204</b>                 | <b>\$ 408,450</b> |

On June 27, 2011, the Company entered into a credit agreement (the "Credit Agreement") along with certain of its subsidiaries, as borrowers (the "Borrowers"), with Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit, and other lenders party thereto. The Credit Agreement replaced the Company's previous \$600.0 million credit facility, which was due to expire in December 2011.

The Credit Agreement consists of a revolving credit facility (the "Revolving Facility") in an aggregate principal amount of \$700.0 million with a final maturity date of June 27, 2016. The maturity date may be extended under certain conditions for an additional one-year term prior to the second anniversary of the initial closing date of June 27, 2011. Up to \$75.0 million of the Revolving Facility is available for the issuance of letters of credit. Additionally, up to \$25.0 million of the Revolving Facility is available to the Company for swing line loans, available on a same-day basis.

## Edgar Filing: IDEX CORP /DE/ - Form 10-Q

Proceeds of the Revolving Facility are available for use by the Borrowers for working capital and other general corporate purposes, including refinancing existing debt of the Company and its subsidiaries. The Company may request increases in the lending commitments under the Credit Agreement, but the aggregate lending commitments may not exceed \$950.0 million. The Company has the right, subject to certain conditions set forth in the Credit Agreement, to designate certain foreign subsidiaries of the Company as borrowers under the Credit Agreement. In connection with any such designation, the Company is required to guarantee the obligations of any such subsidiaries under the Credit Agreement. Under the Credit Agreement, Fluid

**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)**

Management Europe B.V., ( FME ) and IDEX UK Ltd. ( IDEX UK ) were approved by the lenders as designated borrowers. At September 30, 2011, FME had no borrowings under the Revolving Facility, while IDEX UK 's borrowings under the Revolving Facility were £7.0 million (\$10.9 million). As IDEX UK 's borrowings under the Revolving Facility are British Pound denominated and the cash flows that will be used to make payments of principal and interest are predominately generated in British Pounds, the Company does not anticipate any significant foreign exchange gains or losses in servicing this debt.

Borrowings under the Revolving Facility bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, an applicable margin. Such applicable margin is based on the Company 's senior, unsecured, long-term debt rating and can range from .875% to 1.70%. Based on the Company 's credit rating at September 30, 2011, the applicable margin was 1.05%. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the maturity date of the borrowing, or quarterly from the effective date for borrowings exceeding three months. An annual Revolving Facility fee, also based on the Company 's credit rating, is currently 20 basis points and is payable quarterly.

The Credit Agreement requires payment to the lenders of a facility fee based upon (a) the amount of the lenders ' commitments under the Revolving Facility from time to time and (b) the applicable corporate credit ratings of the Company. Voluntary prepayments of any loans and voluntary reductions of the unutilized portion of the commitments under the Revolving Facility are permissible without penalty, subject to break funding payments and minimum notice and minimum reduction amount requirements.

The Credit Agreement contains affirmative and negative covenants that the Company believes are usual and customary for senior unsecured credit agreements, including a financial covenant requiring the maintenance of a 3.25 to 1.0 or lower leverage ratio, which is the ratio of the Company 's consolidated total debt to its consolidated EBITDA, each as defined in the Credit Agreement.

The Credit Agreement also contains customary events of default (subject to grace periods, as appropriate) including among others: nonpayment of principal, interest or fees; breach of the representations or warranties in any material respect; breach of the financial, affirmative or negative covenants; payment default on, or acceleration of, other material indebtedness; bankruptcy or insolvency; material judgments entered against the Company or any of its subsidiaries; certain specified events under the Employee Retirement Income Security Act of 1974, as amended; certain changes in control of the Company; and the invalidity or unenforceability of the Credit Agreement or other documents associated with the Credit Agreement.

At September 30, 2011, there was \$320.9 million outstanding under the Credit Agreement and outstanding letters of credit totaled approximately \$7.3 million. The net available borrowing capacity under the Revolving Facility at September 30, 2011, was approximately \$371.8 million.

On April 18, 2008, the Company completed a \$100.0 million unsecured senior bank term loan agreement ( Term Loan ), with covenants consistent with its credit facility and a maturity on December 21, 2011. At September 30, 2011, there was \$82.0 million outstanding under the Term Loan, which is included within the current portion of long-term debt. Interest under the Term Loan is based on the bank agent 's reference rate or LIBOR plus an applicable margin and is payable at the end of the selected interest period, but at least quarterly. The applicable margin is based on the Company 's senior, unsecured, long-term debt rating and can range from 45 to 100 basis points. Based on the Company 's current debt rating, the applicable margin is 80 basis points.

The Company currently maintains an interest rate exchange agreement related to the Term Loan which expires in December 2011. This interest rate exchange agreement has a current notional amount of \$82.0 million and effectively converted \$100.0 million of floating-rate debt into fixed-rate debt at an interest rate of 4.00%. The fixed rate is comprised of the fixed rate on the interest rate exchange agreement and the Company 's current margin of 80 basis points on the Term Loan.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

On June 9, 2010, the Company completed a private placement of 81.0 million (\$96.8 million) aggregate principal amount of 2.58% Series 2010 Senior Euro Notes due June 9, 2015 ( 2.58% Senior Euro Notes ) pursuant to a Master Note Purchase Agreement, dated June 9, 2010 (the Purchase Agreement ). The Purchase Agreement provides for the issuance of additional series of notes in the future, provided that the aggregate principal amount outstanding under the agreement at any time does not exceed \$750.0 million. The 2.58% Senior Euro Notes bear interest at a rate of 2.58% per annum and will mature on June 9, 2015. The 2.58% Senior Euro Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company's other senior debt. The Company may at any time prepay all or any portion of the 2.58% Senior Euro Notes; provided that any such portion is greater than 5% of the aggregate principal amount of Notes then outstanding under the Purchase Agreement. In the event of a prepayment, the Company will pay an amount equal to par plus accrued interest plus a make-whole premium. The Purchase Agreement contains certain covenants that restrict the Company's ability to, among other things, transfer or sell assets, create liens and engage in certain mergers or consolidations. In addition, the Company must comply with a leverage ratio and interest coverage ratio as set forth in the Purchase Agreement. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding 2.58% Senior Euro Notes will become due and payable immediately without further action or notice. In the case of payment events of defaults, any holder of the 2.58% Senior Euro Notes affected thereby may declare all the 2.58% Senior Euro Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the 2.58% Senior Euro Notes may declare all the 2.58% Senior Euro Notes to be due and payable immediately. The Company used a portion of the proceeds from the 2.58% Senior Euro Notes to pay down existing debt outstanding under its credit facility that had previously been denominated in Euros, with the remainder being available for ongoing business activities.

On December 6, 2010, the Company completed a public offering of \$300.0 million 4.5% senior notes due December 15, 2020 ( 4.5% Senior Notes ). The net proceeds from the offering of approximately \$295.7 million, after deducting the \$1.6 million issuance discount, the \$1.9 million underwriting commission and estimated offering expenses of approximately \$0.8 million, were used to repay \$250.0 million of outstanding bank indebtedness. The balance of the net proceeds was used for general corporate purposes. The 4.5% Senior Notes bear interest at a rate of 4.5% per annum, which is payable semi-annually in arrears on each June 15 and December 15. The Company may redeem all or part of the 4.5% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture ( Indenture ) governing the 4.5% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.5% Senior Notes contain covenants that limit the Company's ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company's assets. The terms of the 4.5% Senior Notes also require the Company to make an offer to repurchase 4.5% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

On April 15, 2010, the Company entered into a forward starting interest rate contract with a notional amount of \$300.0 million with a settlement date in December 2010. This contract was entered into in anticipation of the issuance of the 4.5% Senior Notes and was designed to lock in the market interest rate as of April 15, 2010. The Company settled this interest rate contract in December 2010, resulting in a \$31.0 million payment. The \$31.0 million is being amortized into interest expense over the 10 year term of the 4.5% Senior Notes, which results in an effective interest rate of 5.8%.

On July 12, 2011, the Company entered into a forward starting interest rate contract with a notional amount of \$350.0 million and a settlement date of September 30, 2011. This contract was entered into in anticipation of the issuance of new debt and was designed to lock in the market interest rate as of July 12, 2011. On

**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)**

September 29, 2011, the Company settled this interest rate contract for \$34.4 million (with a payment date of October 3, 2011) and simultaneously entered into a separate interest rate contract with a notional amount of \$350.0 million and a settlement date of February 28, 2012. The contract was entered into to hedge the interest rate exposure of the expected issuance of the new debt and is designed to lock in the market rate as of September 29, 2011. As a result of these two transactions, the Company recorded \$23.2 million, net of tax, in other comprehensive income. The gain or loss resulting from the contracts will be amortized into interest expense over the term of the new debt to be issued.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility, Term Loan, and 2.58% Senior Euro Notes. There are no financial covenants relating to the 4.5% Senior Notes. The most restrictive financial covenants under these debt instruments require a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.25 to 1. At September 30, 2011, the Company was in compliance with both of these financial covenants.

**11. Derivative Instruments**

The Company enters into cash flow hedges to reduce the exposure to variability in certain expected future cash flows. The type of cash flow hedges the Company enters into includes foreign currency contracts and interest rate exchange agreements that effectively convert a portion of floating-rate debt to fixed-rate debt and are designed to reduce the impact of interest rate changes on future interest expense.

The effective portion of gains or losses on interest rate exchange agreements is reported in accumulated other comprehensive income (loss) in shareholders' equity and reclassified into net income in the same period or periods in which the hedged transaction affects net income. The remaining gain or loss in excess of the cumulative change in the present value of future cash flows or the hedged item, if any, is recognized into net income during the period of change.

Fair values relating to derivative financial instruments reflect the estimated amounts that the Company would receive or pay to sell or buy the contracts based on quoted market prices of comparable contracts at each balance sheet date.

At September 30, 2011, the Company had two outstanding interest rate exchange agreements. The first interest rate exchange agreement is a forward setting interest rate contract that currently has a notional amount of \$350.0 million and an effective date of February 28, 2012. The Company will pay fixed interest and will receive floating rate interest based on LIBOR on the effective date of February 28, 2012. This instrument was entered into in anticipation of the expected issuance of \$350.0 million of new debt and was designed to lock in the current market interest rate as of September 29, 2011. The second interest rate exchange agreement, expiring in December 2011, with a current notional amount of \$82.0 million, effectively converted \$100.0 million of floating-rate debt into fixed-rate debt at an interest rate of 4.00%. The fixed rate consists of the fixed rate on the interest rate exchange agreements and the Company's current margin of 80 basis points on the Term Loan.

Approximately \$4.0 million of the gross amount included in accumulated other comprehensive income (loss) in shareholders' equity at September 30, 2011 will be recognized to net income over the next 12 months as the underlying hedged transactions are realized. In addition, after issuance of the new debt, a portion of the forward starting interest rate contracts entered into on July 12, 2011 and September 29, 2011 will be recognized to net income. The amount to be recognized in the next 12 months will be determined based on the settlement date of the forward starting interest rate contract and the issuance of the anticipated new debt.

On May 31, 2011, the Company settled foreign currency exchange contracts with an aggregate notional amount of \$0.5 million; the impact of this settlement was immaterial.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

The following table sets forth the fair value amounts of derivative instruments held by the Company as of September 30, 2011 and December 31, 2010:

|                            | Fair Value Assets<br>(Liabilities) |                      | Balance Sheet Caption |
|----------------------------|------------------------------------|----------------------|-----------------------|
|                            | Sept 30,<br>2011                   | December 31,<br>2010 |                       |
|                            | (In thousands)                     |                      |                       |
| Interest rate agreements   | \$ (36,840)                        | \$ (2,328)           | Accrued expenses      |
| Foreign exchange contracts |                                    | 176                  | Other current assets  |

The following table summarizes the gain (loss) recognized and the amounts and location of income (expense) and gain (loss) reclassified into income for interest rate contracts and foreign currency contracts for September 30, 2011 and 2010:

|                            | Gain (Loss)<br>Recognized in<br>Other<br>Comprehensive<br>Income<br>Three Months Ended September 30, |             | Expense<br>and Gain<br>Reclassified into<br>Income<br>Three Months Ended September 30, |            | Income<br>Statement Caption |
|----------------------------|--|-------------|--|------------|-----------------------------|
|                            | 2011   | 2010        | 2011   | 2010       |                             |
|                            | (In thousands)   |             |  |            |                             |
| Interest rate agreements   | \$ (36,295)  | \$ (16,347) | \$ (1,515)   | \$ (2,146) | Interest expense            |
| Foreign exchange contracts |  | 93          |  | 36         | Sales                       |

|                            | Gain (Loss)<br>Recognized in<br>Other<br>Comprehensive<br>Income<br>Nine Months Ended September 30, |             | Expense<br>and Gain<br>Reclassified into<br>Income<br>Nine Months Ended September 30, |            | Income<br>Statement Caption |
|----------------------------|---|-------------|---|------------|-----------------------------|
|                            | 2011  | 2010        | 2011  | 2010       |                             |
|                            | (In thousands)  |             |   |            |                             |
| Interest rate agreements   | \$ (36,407)   | \$ (43,102) | \$ (4,593)  | \$ (6,751) | Interest expense            |
| Foreign exchange contracts | (55)  | 95          | 227   | 48         | Sales                       |

**12. Fair Value Measurements**

ASC 820 Fair Value Measurements and Disclosures defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The

## Edgar Filing: IDEX CORP /DE/ - Form 10-Q

following is a brief description of those three levels:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs that reflect the reporting entity's own assumptions.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

The following table summarizes the basis used to measure the Company's financial assets and (liabilities) at fair value on a recurring basis in the balance sheet at September 30, 2011 and December 31, 2010:

|                               | <b>Basis of Fair Value Measurements</b> |                |                |                |
|-------------------------------|---|----------------|----------------|----------------|
|                               | <b>Balance</b>                          |                |                |                |
|                               | <b>at<br/>Sept 30, 2011</b>             | <b>Level 1</b> | <b>Level 2</b> | <b>Level 3</b> |
|                               | <b>(In thousands)</b>                   |                |                |                |
| Money market investment       | \$ 15,205                               | \$ 15,205      | \$             | \$             |
| Available for sale securities | 2,487                                   | 2,487          |                |                |
| Contingent consideration      | (2,707)                                 |                |                | (2,707)        |
| Interest rate agreements      | (36,840)                                |                | (36,840)       |                |

|                            | <b>Basis of Fair Value Measurements</b> |                |                |                |
|----------------------------|---|----------------|----------------|----------------|
|                            | <b>Balance at</b>                       |                |                |                |
|                            | <b>December 31, 2010</b>                | <b>Level 1</b> | <b>Level 2</b> | <b>Level 3</b> |
|                            | <b>(In thousands)</b>                   |                |                |                |
| Money market investment    | \$ 96,730                               | \$ 96,730      | \$             | \$             |
| Interest rate agreements   | (2,328)                                 |                | (2,328)        |                |
| Foreign currency contracts | 176                                     |                | 176            |                |

There were no transfers of assets or liabilities between Level 1 and Level 2 during the first nine months in 2011 or 2010.

In determining the fair value of the Company's interest rate exchange agreement derivatives, the Company used a present value of expected cash flows based on market observable interest rate yield curves commensurate with the term of each instrument and the credit default swap market to reflect the credit risk of either the Company or the counterparty.

In determining the fair value of the Company's contingent consideration, the Company used a probability weighted estimate based on an independent appraisal, adjusted for the time value of money.

The carrying value of our cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair values because of the short term nature of these instruments. At September 30, 2011, the fair value of our Revolving Facility, Term Loan, 2.58% Senior Euro Notes and 4.5% Senior Notes, based on quoted market prices and current market rates for debt with similar credit risk and maturity, was approximately \$803.0 million compared to the carrying value of \$811.6 million.

**13. Common and Preferred Stock**

At September 30, 2011 and December 31, 2010, the Company had 150 million shares of authorized common stock, with a par value of \$.01 per share, and 5 million shares of authorized preferred stock, with a par value of \$.01 per share. No preferred stock was issued at September 30, 2011 and December 31, 2010.

**14. Share-Based Compensation**

During the nine months ended September 30, 2011, the Company granted approximately 0.8 million stock options and 0.3 million unvested shares, respectively. During the nine months ended September 30, 2010, the Company granted approximately 0.9 million stock options and



0.3 million unvested shares, respectively.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

Weighted average option fair values and assumptions for the periods specified are disclosed in the following table:

|                                       | <b>Three Months Ended September 30,</b> |               |
|---------------------------------------|---|---------------|
|                                       | <b>2011</b>                             | <b>2010</b>   |
| Weighted average fair value of grants | \$11.66                                 | \$ 8.01       |
| Dividend yield                        | 1.63%                                   | 2.05%         |
| Volatility                            | 31.84%                                  | 33.01%        |
| Risk-free forward interest rate       | 0.18% - 5.15%                           | 0.31% - 4.88% |
| Expected life (in years)              | 6.08                                    | 5.96          |

|                                       | <b>Nine Months Ended September 30,</b> |               |
|---------------------------------------|--|---------------|
|                                       | <b>2011</b>                            | <b>2010</b>   |
| Weighted average fair value of grants | \$ 12.31                               | \$ 9.53       |
| Dividend yield                        | 1.45%                                  | 1.51%         |
| Volatility                            | 32.72%                                 | 33.44%        |
| Risk-free forward interest rate       | 0.28% - 5.62%                          | 0.32% - 5.68% |
| Expected life (in years)              | 6.14                                   | 5.98          |

The assumptions are as follows:

The Company estimated volatility using its historical share price performance over the contractual term of the option.

The Company uses historical data to estimate the expected life of the option. The expected life assumption for the three and nine months ended September 30, 2011 and 2010 is an output of the Binomial lattice option-pricing model, which incorporates vesting provisions, rate of voluntary exercise and rate of post-vesting termination over the contractual life of the option to define expected employee behavior.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option. For the three and nine months ended September 30, 2011 and 2010, we present the range of risk-free one-year forward rates, derived from the U.S. treasury yield curve, utilized in the Binomial lattice option-pricing model.

The expected dividend yield is based on the Company's current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the option.

The Company's policy is to recognize compensation cost on a straight-line basis over the requisite service period for the entire award. Additionally, the Company's general policy is to issue authorized and unissued shares of common stock to satisfy stock option exercises or grants of unvested shares.



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

Total compensation cost for the stock options is as follows:

|  | Three Months                                  |          | Nine Months                                   |          |
|--|---|----------|---|----------|
|  | Ended<br>September 30,<br>2011 <sup>(1)</sup> | 2010     | Ended<br>September 30,<br>2011 <sup>(1)</sup> | 2010     |
|  | (In thousands)                                |          |   |          |
| Cost of goods sold                           | \$ 202  | \$ 124   | \$ 645  | \$ 653   |
| Selling, general and administrative expenses | 1,157   | 1,402    | 5,140   | 5,265    |
| Total expense before income taxes            | 1,359   | 1,526    | 5,785   | 5,918    |
| Income tax benefit                           | (390)   | (474)    | (1,842)                                       | (1,887)  |
| Total expense after income taxes             | \$ 969  | \$ 1,052 | \$ 3,943                                      | \$ 4,031 |

(1) Reflects the forfeiture of stock options related to the Company's transition to a new CEO in August 2011.

Total compensation cost for the unvested shares is as follows:

|  | Three Months                                  |          | Nine Months                                   |          |
|--|---|----------|---|----------|
|  | Ended<br>September 30,<br>2011 <sup>(1)</sup> | 2010     | Ended<br>September 30,<br>2011 <sup>(1)</sup> | 2010     |
|  | (In thousands)                                |          |   |          |
| Cost of goods sold                           | \$ 197  | \$ (42)  | \$ 495  | \$ 223   |
| Selling, general and administrative expenses | (1,883)                                       | 2,044    | 3,475   | 6,717    |
| Total expense before income taxes            | (1,686)                                       | 2,002    | 3,970   | 6,940    |
| Income tax benefit                           | (451)   | (398)    | (1,537)                                       | (1,448)  |
| Total (benefit) expense after income taxes   | \$ (2,137)                                    | \$ 1,604 | \$ 2,433                                      | \$ 5,492 |

(1) Reflects the forfeiture of unvested shares related to the Company's transition to a new CEO in August 2011.

Classification of stock compensation cost within the Consolidated Statements of Operations is consistent with classification of cash compensation for the same employees and \$0.1 million of compensation cost was capitalized as part of inventory.

As of September 30, 2011, there was \$10.0 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.4 years, and \$10.0 million of total unrecognized compensation cost related to unvested shares that is expected to be recognized over a weighted-average period of 1.2 years.



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)****15. Retirement Benefits**

The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans and other postretirement plans for its employees. The following tables provide the components of net periodic benefit cost for its major defined benefit plans and its other postretirement plans.

|                                | Pension Benefits                 |          |          |          | Pension Benefits                |          |          |          |
|--------------------------------|----------------------------------|----------|----------|----------|---------------------------------|----------|----------|----------|
|                                | Three Months Ended September 30, |          | 2010     |          | Nine Months Ended September 30, |          | 2010     |          |
|                                | 2011                             | Non-U.S. | U.S.     | Non-U.S. | 2011                            | Non-U.S. | U.S.     | Non-U.S. |
|                                | (In thousands)                   |          |          |          |                                 |          |          |          |
| Service cost                   | \$ 399                           | \$ 207   | \$ 311   | \$ 173   | \$ 1,319                        | \$ 620   | \$ 1,249 | \$ 357   |
| Interest cost                  | 1,116                            | 587      | 1,114    | 519      | 3,380                           | 1,756    | 3,393    | 1,071    |
| Expected return on plan assets | (1,171)                          | (278)    | (1,081)  | (80)     | (3,567)                         | (837)    | (3,297)  | (163)    |
| Net amortization               | 1,261                            | 111      | 1,047    | 72       | 3,423                           | 334      | 3,301    | 148      |
| Net periodic benefit cost      | \$ 1,605                         | \$ 627   | \$ 1,391 | \$ 684   | \$ 4,555                        | \$ 1,873 | \$ 4,646 | \$ 1,413 |

|                           | Other Postretirement Benefits |        |                   |        |
|---------------------------|-------------------------------|--------|-------------------|--------|
|                           | Three Months Ended            |        | Nine Months Ended |        |
|                           | September 30,                 | 2010   | September 30,     | 2010   |
|                           | (In thousands)                |        |                   |        |
| Service cost              | \$ 173                        | \$ 130 | \$ 519            | \$ 390 |
| Interest cost             | 259                           | 259    | 778               | 778    |
| Net amortization          | (39)                          | (87)   | (117)             | (262)  |
| Net periodic benefit cost | \$ 393                        | \$ 302 | \$ 1,180          | \$ 906 |

The Company previously disclosed in its financial statements for the year ended December 31, 2010, that it expected to contribute approximately \$7.9 million to its pension plans and \$1.0 million to its other postretirement benefit plans in 2011. As of September 30, 2011, \$6.1 million of contributions have been made to its pension plans and \$0.6 million have been made to its other postretirement benefit plans. The Company presently anticipates contributing up to an additional \$2.2 million in 2011 to fund its pension plans and other postretirement benefit plans.

**16. Legal Proceedings**

The Company is party to various legal proceedings arising in the ordinary course of business, none of which are expected to have a material adverse effect on its business, financial condition, results of operations or cash flows.

**17. Income Taxes**

## Edgar Filing: IDEX CORP /DE/ - Form 10-Q

The Company's provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes decreased to \$14.8 million in the third quarter of 2011 from \$18.6 million in the third quarter of 2010. The effective tax rate decreased to 23.4% for the third quarter of 2011 compared to 32.6% in the third quarter of 2010 primarily due to the mix of global pre-tax income among jurisdictions and as a result of recent acquisitions.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****(unaudited)**

The provision for income taxes increased to \$60.2 million in the first nine months of 2011 from \$55.7 million in the same period of 2010. The effective tax rate decreased to 29.1% for the first nine months of 2011 compared to 32.5% in the same period of 2010 primarily due to the mix of global pre-tax income among jurisdictions and as a result of recent acquisitions.

The Company and its subsidiaries file U.S. federal income tax returns and various state and foreign income tax returns. Due to the potential for resolution of federal, state and foreign examinations, and the expiration of various statutes of limitation, it is reasonably possible that the Company's gross unrecognized tax benefits balance may change within the next twelve months by a range of zero to \$3.1 million.

**18. Comprehensive Income**

The components of comprehensive income (loss) are as follows:

|   | <b>Three Months</b>   |             | <b>Nine Months</b>   |             |
|---|-----------------------|-------------|----------------------|-------------|
|   | <b>Ended</b>          |             | <b>Ended</b>         |             |
|   | <b>September 30,</b>  |             | <b>September 30,</b> |             |
|   | <b>2011</b>           | <b>2010</b> | <b>2011</b>          | <b>2010</b> |
|   | <b>(In thousands)</b> |             |                      |             |
| Net income  | \$ 48,336             | \$ 38,564   | \$ 146,469           | \$ 115,587  |
| Other comprehensive income                          |                       |             |                      |             |
| Unrealized loss on derivatives, net of tax          | (22,162)              | (9,080)     | (20,398)             | (23,076)    |
| Pension and other post-retirement plans, net of tax | 777                   | (12)        | 2,354                | 728         |
| Cumulative translation adjustment                   | (26,437)              | 38,678      | 5,100                | (12,187)    |
| Comprehensive income (loss)                         | \$ 514                | \$ 68,150   | \$ 133,525           | \$ 81,052   |

Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries.



---

**Table of Contents**

**Item 2. *Management's Discussion and Analysis of Financial Condition and Results of Operations.***

**Cautionary Statement Under the Private Securities Litigation Reform Act**

The Historical Overview and the Liquidity and Capital Resources sections of this management's discussion and analysis of financial condition and results of operations contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. These statements relate to, among other things, operating results and are indicated by words or phrases such as expects, should, will, and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those statements. The risks and uncertainties include, but are not limited to, IDEX Corporation's ( IDEX or the Company ) ability to integrate and operate acquired businesses on a profitable basis and other risks and uncertainties identified under the heading Risk Factors in item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent periodic reports filed by IDEX with the Securities and Exchange Commission. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

**Overview**

IDEX is an applied solutions company specializing in fluid and metering technologies, health and science technologies, dispensing equipment, and fire, safety and other diversified products built to its customers' specifications. IDEX's products are sold in niche markets to a wide range of industries throughout the world. Accordingly, its businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where IDEX does business and by the relationship of the U.S. dollar to other currencies. Levels of capacity utilization and capital spending in certain industries and overall industrial activity are among the factors that influence the demand for IDEX's products.

The Company has four reportable segments: Fluid & Metering Technologies, Health & Science Technologies, Dispensing Equipment and Fire & Safety/Diversified Products.

The Fluid & Metering Technologies Segment designs, produces and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems and provides flow monitoring and other services for water and wastewater. The Health & Science Technologies Segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets, and precision gear and peristaltic pump technologies that meet exacting OEM specifications. The Dispensing Equipment Segment produces precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses. The Fire & Safety/Diversified Products Segment produces firefighting pumps and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, and engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications.

**Results of Operations**

The following is a discussion and analysis of our results of operations for the three and nine month periods ended September 30, 2011 and 2010. For purposes of this discussion and analysis, reference is made to the table below and the Company's Consolidated Statements of Operations included in Item 1. Certain prior year amounts have been revised to reflect the movement of the Pharma group from the Fluid & Metering Technologies Segment to the Health & Science Technologies Segment.

---

**Table of Contents**

***Performance in the Three Months Ended September 30, 2011 Compared with the Same Period of 2010***

Sales in the three months ended September 30, 2011 were \$476.9 million, a 28% increase from the comparable period last year. This increase reflects a 9% increase in organic sales, 16% from acquisitions (Fitzpatrick November 2010, AT Films January 2011, Microfluidics March 2011 and CVI MG June 2011) and 3% favorable foreign currency translation. Sales to international customers represented approximately 53% of total sales in the current period compared with 50% in the same period in 2010.

For the third quarter of 2011, Fluid & Metering Technologies contributed 43% of sales and 50% of operating income; Health & Science Technologies accounted for 37% of sales and 26% of operating income; Dispensing Equipment accounted for 5% of sales and 1% of operating income; and Fire & Safety/Diversified Products represented 15% of sales and 23% of operating income.

Fluid & Metering Technologies sales of \$201.9 million increased \$32.2 million, or 19% in the third quarter of 2011 compared with 2010. This reflects 16% organic growth and 3% favorable foreign currency translation. The increase in organic sales was driven by strong global growth across energy, chemical and agriculture end markets. In the third quarter of 2011, organic sales increased approximately 14% domestically and 18% internationally. Organic sales to customers outside the U.S. were approximately 46% of total segment sales during the third quarter of both 2011 and 2010. Health & Science Technologies sales of \$176.8 million increased \$65.3 million, or 59% in the third quarter of 2011 compared with 2010. This reflects 4% organic growth, 54% growth from acquisitions (Fitzpatrick, AT Films, Microfluidics and CVI MG) and 1% favorable foreign currency translation. The organic growth reflects strength in pharma, industrial and environmental markets. In the third quarter of 2011, organic sales decreased 9% domestically and increased 19% internationally. Organic sales to customers outside the U.S. were approximately 54% of total segment sales in the third quarter of 2011, compared with 43% in 2010.

Dispensing Equipment sales of \$25.1 million decreased \$1.3 million, or 5% in the third quarter of 2011 compared with 2010. This reflects 11% organic decline, partially offset by a 6% favorable foreign currency translation. The decrease in organic sales was due to market softness in North America, partially offset by strength in Asia and Eastern Europe. In the third quarter of 2011, organic sales decreased 17% domestically and 9% internationally. Organic sales to customers outside the U.S. were approximately 74% of total segment sales in the third quarter of both 2011 and 2010.

Fire & Safety/Diversified Products sales of \$73.6 million increased \$6.6 million, or 10% in the third quarter of 2011 compared with 2010. This reflects 6% organic growth and 4% favorable foreign currency translation. The change in organic sales reflects strength in rescue equipment and engineered band clamping systems, partially offset by weakness in fire suppression. In the third quarter of 2011, organic sales increased 7% domestically and 6% internationally. Organic sales to customers outside the U.S. were approximately 55% of total segment sales in the third quarter of 2011, compared with 56% in 2010.

**Table of Contents**

|   | Three Months                               |                     | Nine Months                                |                     |
|---|--|---------------------|--|---------------------|
|   | Ended September 30, <sup>(1)</sup><br>2011 | 2010 <sup>(4)</sup> | Ended September 30, <sup>(1)</sup><br>2011 | 2010 <sup>(4)</sup> |
| (In thousands)                                |  |                     |  |                     |
| <b>Fluid &amp; Metering Technologies</b>      |  |                     |  |                     |
| Net sales                                     | \$ 201,944                                 | \$ 169,770          | \$ 602,468                                 | \$ 505,681          |
| Operating income <sup>(2)</sup>               | 39,519                                     | 29,941              | 120,044                                    | 90,391              |
| Operating margin                              | 19.6%                                      | 17.6%               | 19.9%                                      | 17.9%               |
| Depreciation and amortization                 | \$ 8,577                                   | \$ 8,046            | \$ 24,757                                  | \$ 23,678           |
| Capital expenditures                          | 3,301                                      | 3,356               | 9,808                                      | 12,987              |
| <b>Health &amp; Science Technologies</b>      |  |                     |  |                     |
| Net sales                                     | \$ 176,764                                 | \$ 111,430          | \$ 454,518                                 | \$ 310,952          |
| Operating income <sup>(2)</sup>               | 20,651                                     | 23,274              | 79,830                                     | 64,186              |
| Operating margin                              | 11.7%                                      | 20.9%               | 17.6%                                      | 20.6%               |
| Depreciation and amortization                 | \$ 9,738                                   | \$ 4,929            | \$ 20,770                                  | \$ 13,401           |
| Capital expenditures                          | 4,607                                      | 2,298               | 9,930                                      | 6,102               |
| <b>Dispensing Equipment</b>                   |  |                     |  |                     |
| Net sales                                     | \$ 25,143                                  | \$ 26,480           | \$ 93,447                                  | \$ 101,169          |
| Operating income <sup>(2)</sup>               | 946  | 2,711               | 16,962                                     | 19,062              |
| Operating margin                              | 3.8%                                       | 10.2%               | 18.2%                                      | 18.8%               |
| Depreciation and amortization                 | \$ 595                                     | \$ 816              | \$ 2,519                                   | \$ 2,980            |
| Capital expenditures                          | 123  | 245                 | 973  | 887                 |
| <b>Fire &amp; Safety/Diversified Products</b> |  |                     |  |                     |
| Net sales                                     | \$ 73,592                                  | \$ 66,993           | \$ 209,367                                 | \$ 194,385          |
| Operating income <sup>(2)</sup>               | 18,317                                     | 17,045              | 50,308                                     | 44,032              |
| Operating margin                              | 24.9%                                      | 25.4%               | 24.0%                                      | 22.7%               |
| Depreciation and amortization                 | \$ 1,249                                   | \$ 1,195            | \$ 4,042                                   | \$ 3,993            |
| Capital expenditures                          | 1,401                                      | 786                 | 3,612                                      | 2,662               |
| <b>Total IDEX</b>                             |  |                     |  |                     |
| Net sales                                     | \$ 476,881                                 | \$ 373,731          | \$ 1,357,768                               | \$ 1,107,855        |
| Operating income <sup>(2)</sup>               | 71,305                                     | 62,439              | 228,655                                    | 183,112             |
| Operating margin                              | 15.0%                                      | 16.7%               | 16.8%                                      | 16.5%               |
| Depreciation and amortization <sup>(3)</sup>  | \$ 20,540                                  | \$ 15,235           | \$ 53,116                                  | \$ 44,888           |
| Capital expenditures                          | 10,048                                     | 7,936               | 27,136                                     | 25,972              |

(1) Three and nine month data includes acquisitions of Periflo (September 2010) and OBL (July 2010) in the Fluid & Metering Technologies Segment and CVI MG (June 2011), Microfluidics (March 2011), AT Films (January 2011), Fitzpatrick (November 2010) and Seals/PPE (April 2010) in the Health & Science Technologies Segment from the respective dates of acquisition.

(2) Group operating income excludes unallocated corporate operating expenses.

(3) Excludes amortization of debt issuance expenses.

(4) Revised to reflect the movement of the Pharma group from the Fluid & Metering Technologies Segment to the Health & Science Technologies Segment.

Gross profit of \$181.5 million in the third quarter of 2011 increased \$27.4 million, or 18% from 2010. Gross profit as a percent of sales was 38.1% in the third quarter of 2011 and 41.2% in 2010. The decrease in gross margin primarily reflects an acquisition fair value inventory charge of \$12.8 million for CVI MG, partially offset by higher volume.

Selling, general and administrative ( SG&A ) expenses increased to \$107.3 million in the third quarter of 2011 from \$88.2 million in 2010. The \$19.1 million increase reflects approximately \$5.8 million in volume-related expenses, \$15.6 million for incremental costs from new acquisitions and \$0.4 million of acquisition-



**Table of Contents**

related costs, partially offset by a \$2.7 million gain from the reversal of previously recorded costs related to the Company's transition to a new CEO in August 2011. As a percentage of sales, SG&A expenses were 22.5% for 2011 and 23.6% for 2010.

During the three months ended September 30, 2011, the Company recorded pre-tax restructuring expenses totaling \$2.9 million, while \$3.5 million was recorded for the same period in 2010. These restructuring expenses were mainly attributable to employee severance related to employee reductions across various functional areas and facility rationalization resulting from the Company's cost savings initiatives.

Operating income of \$71.3 million in the third quarter of 2011 was up from the \$62.4 million recorded in 2010, primarily reflecting an increase in volume and improved productivity. Operating margin of 15.0% in the third quarter 2011 was down from 16.7% in 2010 primarily due to an inventory fair value charge associated with the CVI MG acquisition, partially offset by higher volume. In the Fluid & Metering Technologies Segment, operating income of \$39.5 million and operating margins of 19.6% in the third quarter of 2011 were up from the \$29.9 million and 17.6% recorded in 2010 principally due to improved productivity and cost reduction initiatives. In the Health & Science Technologies Segment, operating income of \$20.7 million and operating margins of 11.7% in the third quarter of 2011 were down from the \$23.3 million and 20.9% recorded in 2010, primarily due to the inventory fair value charge of \$12.8 million associated with the CVI MG acquisition, partially offset by higher volume. In the Dispensing Equipment Segment, operating income of \$0.9 million and operating margins of 3.8% in the third quarter of 2011 were down from the \$2.7 million of operating income and 10.2% recorded in 2010, primarily due to lower volume and restructuring related costs, partially offset by productivity and cost savings initiatives. Operating income and operating margins in the Fire & Safety/Diversified Products Segment of \$18.3 million and 24.9%, respectively, were higher than the \$17.0 million and 25.4% recorded in 2010, primarily due to volume leverage and favorable product mix. The Company incurred \$13.2 million of acquisition related transaction costs and fair value inventory charges in the third quarter of 2011, of which \$0.4 million was recorded in selling, general and administrative expense and \$12.8 million was recorded in cost of sales.

Other expense of \$0.4 million in 2011 was lower than the \$1.1 million recorded in 2010, primarily due to higher losses on foreign currency transactions in 2010.

Interest expense increased to \$7.8 million in 2011 from \$4.2 million in 2010. The increase was principally due to higher debt levels issued in conjunction with the CVI MG acquisition.

The provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes decreased to \$14.7 million in the third quarter of 2011 compared to the third quarter of 2010, which was \$18.6 million. The effective tax rate decreased to 23.4% for the third quarter of 2011 compared to 32.6% in the third quarter of 2010 primarily due to the mix of global pre-tax income among jurisdictions and as a result of recent acquisitions.

Net income for the current quarter of \$48.3 million increased from the \$38.6 million earned in 2010. Diluted earnings per share in the third quarter of 2011 of \$0.58 increased \$0.11, or 23%, compared with 2010.

***Performance in the Nine Months Ended September 30, 2011 Compared with the Same Period of 2010***

Sales in the nine months ended September 30, 2011 were \$1,357.8 million, a 23% increase from the comparable period last year. This increase reflects a 10% increase in organic sales, 10% from acquisitions (Seals/PPE April 2010, OBL July 2010, Periflo September 2010, Fitzpatrick November 2010, AT Films January 2011, Microfluidics March 2011 and CVI MG June 2011) and 3% favorable foreign currency translation. Sales to international customers represented approximately 52% of total sales in the current period compared with 48% in 2010.

For the first nine months of 2011, Fluid & Metering Technologies contributed 44% of sales and 45% of operating income; Health & Science Technologies accounted for 34% of sales and 30% of operating income; Dispensing Equipment accounted for 7% of sales and 6% of operating income; and Fire & Safety/Diversified Products represented 15% of sales and 19% of operating income.

---

**Table of Contents**

Fluid & Metering Technologies sales of \$602.5 million for the nine months ended September 30, 2011 increased \$96.8 million, or 19% compared with 2010, reflecting 16% organic growth, 1% growth from acquisitions (OBL and Periflo) and 2% favorable foreign currency translation. The increase in organic sales was driven by strong global growth in agriculture, chemical and energy. In the first nine months of 2011, organic sales increased approximately 14% domestically and 17% internationally. Organic sales to customers outside the U.S. were approximately 46% of total segment sales during the first nine months of 2011, compared to 45% in the same period in 2010.

Health & Science Technologies sales of \$454.5 million increased \$143.6 million, or 46% in the first nine months of 2011 compared with 2010. This reflects 10% organic growth, 35% growth from acquisitions (Seals/PPE, Fitzpatrick, AT Films, Microfluidics and CVI MG) and 1% favorable foreign currency translation. The organic growth reflects strength across all Health & Science Technologies product markets. In the first nine months of 2011, organic sales decreased 1% domestically and increased 24% internationally. Organic sales to customers outside the U.S. were approximately 50% of total segment sales in the first nine months of 2011, compared with 41% in 2010.

Dispensing Equipment sales of \$93.4 million decreased \$7.7 million, or 8% in the first nine months of 2011 compared with 2010. This change reflects a 13% organic decline, partially offset by a 5% favorable foreign currency translation. The decrease in organic sales was due to market softness in North America, partially offset by strength in Eastern Europe and Asia. In the first nine months of 2011, organic sales decreased 48% domestically, primarily due to North American replenishment programs in 2010 and increased 5% internationally. Organic sales to customers outside the U.S. were approximately 79% of total segment sales in the first nine months of 2011, compared with 66% in 2010.

Fire & Safety/Diversified Products sales of \$209.4 million increased \$15.0 million, or 8% in the first nine months of 2011 compared with 2010. This change reflects 5% organic growth and a 3% favorable foreign currency translation. The change in organic sales reflects strength in rescue equipment and engineered band clamping systems, partially offset by weakness in fire suppression. In the first nine months of 2011, organic sales increased 5% both domestically and internationally. Organic sales to customers outside the U.S. were approximately 54% of total segment sales in the first nine months of 2011, compared with 55% in 2010.

Gross profit of \$545.1 million in the first nine months of 2011 increased \$88.6 million, or 19% from 2010. Gross profit as a percent of sales was 40.1% in the first nine months of 2011 and 41.2% in 2010. The decrease in gross margin primarily reflects acquisition fair value inventory charges of \$15.8 million, partially offset by higher volume and product mix.

SG&A expenses increased to \$313.5 million in the first nine months of 2011 from \$267.0 million in 2010. The \$46.5 million increase reflects approximately \$15.9 million in volume-related expenses, \$30.4 million for incremental costs associated with acquisitions and \$5.7 million of acquisition-related costs, partially offset by a \$2.8 million gain from the sale of a facility in Italy and \$2.7 million from the reversal of previously recorded costs related to the CEO transition. As a percent of sales, SG&A expenses were 23.1% for 2011 and 24.1% for 2010.

During the nine months ended September 30, 2011, the Company recorded pre-tax restructuring expenses totaling \$2.9 million, while \$6.4 million was recorded for the same period in 2010. These restructuring expenses were mainly attributable to employee severance related to employee reductions across various functional areas and facility rationalization resulting from the Company's cost savings initiatives.

Operating income of \$228.7 million and operating margins of 16.8% in the first nine months of 2011 were up from the \$183.1 million and 16.5% recorded in 2010, primarily reflecting an increase in volume, improved productivity and a gain from the sale of a facility in Italy, partially offset by acquisition fair value inventory charges and acquisition-related costs. In the Fluid & Metering Technologies Segment, operating income of \$120.0 million and operating margins of 19.9% in the first nine months of 2011 were up from the \$90.4 million and 17.9% recorded in 2010 principally due to higher sales, sourcing initiatives, strategic pricing and cost

**Table of Contents**

control. In the Health & Science Technologies Segment, operating income of \$79.8 million in the first nine months of 2011 was up from the \$64.2 million recorded in 2010 due to volume leverage, improved mix with new products and increased content on OEM platforms, partially offset by the inventory fair value charge associated with the CVI MG acquisition. Operating margin in the Health & Science Technologies Segment of 17.6% in the first nine months of 2011 was down from 20.6% in 2010 primarily due to an inventory fair value charge associated with the CVI MG acquisition, partially offset by higher volume. In the Dispensing Equipment Segment, operating income of \$17.0 million and operating margins of 18.2% in the first nine months of 2011 were down from the \$19.1 million of operating income and 18.8% recorded in 2010, primarily due to lower volume and restructuring related costs, partially offset by a gain from the sale of a facility in Italy. Operating income and operating margins in the Fire & Safety/Diversified Products Segment of \$50.3 million and 24.0%, respectively, were higher than the \$44.0 million and 22.7% recorded in 2010, primarily due to volume leverage and favorable product mix. The Company incurred \$22.5 million of acquisition related transaction costs and fair value inventory charges in the first nine months of 2011, of which \$5.7 million was recorded in selling, general and administrative expense and \$16.8 million was recorded in cost of sales.

Other expense of \$1.0 million in 2011 was higher than the \$0.6 million expense in 2010, due to higher losses on foreign currency transactions in 2011.

Interest expense increased to \$20.9 million in 2011 from \$11.2 million in 2010. The increase was principally due to higher debt levels issued in conjunction with the CVI MG acquisition.

The provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes increased to \$60.2 million for the first nine months of 2011 compared to the same period in 2010, which was \$55.7 million. The effective tax rate decreased to 29.1% for the first nine months of 2011 compared to 32.5% in the same period of 2010 primarily due to the mix of global pre-tax income among jurisdictions and as a result of recent acquisitions.

Net income for the first nine months of 2011 of \$146.5 million increased from the \$115.6 million earned in 2010. Diluted earnings per share in the first nine months of 2011 of \$1.75 increased \$0.35, or 25%, compared with 2010.

**Liquidity and Capital Resources**

At September 30, 2011, working capital was \$412.1 million and the current ratio was 2.0 to 1. Cash flows from operating activities for the first nine months of 2011 increased \$18.3 million, or 12%, to \$175.6 million compared to the first nine months of 2010 mainly due to increased volume.

Cash flows provided by operating activities were more than adequate to fund capital expenditures of \$28.0 million and \$26.0 million in the first nine months of 2011 and 2010, respectively. Capital expenditures were generally for machinery and equipment that improved productivity and tooling to support the Company's global sourcing initiatives, although a portion was for business system technology and replacement of equipment and facilities. The Company expects full year 2011 capital expenditures to be in the range of \$36.0 to \$38.0 million. Management believes that the Company has ample capacity in its plants and equipment to meet expected needs for future growth.

The Company completed the acquisitions of AT Films on January 20, 2011 for cash consideration of \$31.8 million and contingent consideration valued at approximately \$2.7 million, Microfluidics on March 11, 2011 for cash consideration of \$18.5 million and CVI MG on June 10, 2011 for cash consideration of \$395.7 million and the assumption of approximately \$1.4 million of debt. Approximately \$365.0 million of the cash payment for CVI MG was financed with borrowings under the Company's Revolving Facility and the remaining cash payments were funded from cash on hand.

The Company maintains the Revolving Facility, which is a \$700.0 million unsecured, multi-currency bank credit facility expiring on June 27, 2016. At September 30, 2011, there was \$320.9 million outstanding under the

---

**Table of Contents**

Revolving Facility and outstanding letters of credit totaled approximately \$7.3 million. The net available borrowing capacity under the Revolving Facility at September 30, 2011, was approximately \$371.8 million. Borrowings under the Revolving Facility bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, in each case, an applicable margin. Such applicable margin is based on the Company's senior, unsecured, long-term debt rating and can range from .875% to 1.70%. Based on the Company's credit rating at September 30, 2011, the applicable margin was 1.05%. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the maturity date of the borrowing, or quarterly from the effective date for borrowings exceeding three months. An annual Revolving Facility fee, also based on the Company's credit rating, is currently 20 basis points and is payable quarterly.

On April 18, 2008, the Company completed a \$100.0 million unsecured senior bank term loan agreement (Term Loan), with covenants consistent with its credit facility and a maturity on December 21, 2011. At September 30, 2011, there was \$82.0 million outstanding under the Term Loan, which was included within the current portion of long-term debt. Interest under the Term Loan is based on the bank agent's reference rate or LIBOR plus an applicable margin and is payable at the end of the selected interest period, but at least quarterly. The applicable margin is based on the Company's senior, unsecured, long-term debt rating and can range from 45 to 100 basis points. Based on the Company's current debt rating, the applicable margin is 80 basis points. The Company currently maintains an interest rate exchange agreement related to the Term Loan which expires in December 2011. This interest rate exchange agreement has a current notional amount of \$82.0 million and effectively converts \$100.0 million of floating-rate debt into fixed-rate debt at an interest rate of 4.00%. The fixed rate consists of the fixed rate on the interest rate exchange agreement and the Company's current margin of 80 basis points on the Term Loan.

On June 9, 2010, the Company completed a private placement of \$101.0 million (\$96.8 million) aggregate principal amount of 2.58% Series 2010 Senior Euro Notes due June 9, 2015 (2.58% Senior Euro Notes) pursuant to a Master Note Purchase Agreement, dated June 9, 2010 (the Purchase Agreement). The Purchase Agreement provides for the issuance of additional series of notes in the future, provided that the aggregate principal amount outstanding under the agreement at any time does not exceed \$750.0 million. The 2.58% Senior Euro Notes bear interest at a rate of 2.58% per annum and will mature on June 9, 2015. The 2.58% Senior Euro Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company's other senior debt. The Company may at any time prepay all or any portion of the 2.58% Senior Euro Notes; provided that any such portion is greater than 5% of the aggregate principal amount of Notes then outstanding under the Purchase Agreement. In the event of a prepayment, the Company will pay an amount equal to par plus accrued interest plus a make-whole premium. The Purchase Agreement contains certain covenants that restrict the Company's ability to, among other things, transfer or sell assets, create liens and engage in certain mergers or consolidations. In addition, the Company must comply with a leverage ratio and interest coverage ratio as set forth in the Purchase Agreement. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding 2.58% Senior Euro Notes will become due and payable immediately without further action or notice. In the case of payment events of defaults, any holder of the 2.58% Senior Euro Notes affected thereby may declare all the 2.58% Senior Euro Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the 2.58% Senior Euro Notes may declare all the 2.58% Senior Euro Notes to be due and payable immediately. The Company used a portion of the proceeds from the 2.58% Senior Notes to pay down existing debt outstanding under its credit facility that had previously been denominated in Euros, with the remainder being available for ongoing business activities.

On December 6, 2010, the Company completed a public offering of \$300.0 million 4.5% senior notes due December 15, 2020 (4.5% Senior Notes). The net proceeds from the offering of approximately \$295.7 million, after deducting the \$1.6 million issuance discount, the \$1.9 million underwriting commission and estimated offering expenses of approximately \$0.8 million, were used to repay \$250.0 million of outstanding bank indebtedness. The balance of the net proceeds was used for general corporate purposes. The 4.5% Senior Notes bear interest at a rate of 4.5% per annum, which is payable semi-annually in arrears on each June 15 and December 15. The Company may redeem all or part of the 4.5% Senior Notes at any time prior to maturity at the



**Table of Contents**

redemption prices set forth in the Note Indenture ( Indenture ) governing the 4.5% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.5% Senior Notes contain covenants that limit the Company's ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company's assets. The terms of the 4.5% Senior Notes also require the Company to make an offer to repurchase 4.5% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

On April 15, 2010, the Company entered into a forward starting interest rate contract with a notional amount of \$300.0 million with a settlement date in December 2010. This contract was entered into in anticipation of the issuance of the 4.5% Senior Notes and was designed to lock in the market interest rate as of April 15, 2010. The Company settled this interest rate contract in December 2010, resulting in a \$31.0 million payment. The \$31.0 million is being amortized into interest expense over the 10 year term of the 4.5% Senior Notes, which results in an effective interest rate of 5.8%.

On July 12, 2011, the Company entered into a forward starting interest rate contract with a notional amount of \$350.0 million and a settlement date of September 30, 2011. This contract was entered into in anticipation of the issuance of new debt and was designed to lock in the market interest rate as of July 12, 2011. On September 29, 2011, the Company settled this interest rate contract for \$34.4 million (with a payment date of October 3, 2011) and simultaneously entered into a separate interest rate contract with a notional amount of \$350.0 million and a settlement date of February 28, 2012. The contract was entered into to hedge the interest rate exposure of the expected issuance of the new debt and is designed to lock in the market rate as of September 29, 2011. As a result of these two transactions, the Company recorded \$23.2 million, net of tax, in other comprehensive income. The gain or loss resulting from the contracts will be amortized into interest expense over the term of the new debt to be issued.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility, Term Loan, and 2.58% Senior Euro Notes. There are no financial covenants relating to the 4.5% Senior Notes. The most restrictive financial covenants under these debt instruments require a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.25 to 1. At September 30, 2011, the Company was in compliance with both of these financial covenants.

The Company believes current cash and cash that will be generated from operations will be sufficient to meet its operating cash requirements, planned capital expenditures, interest on all borrowings, pension and postretirement funding requirements and annual dividend payments to holders of the Company's stock for the remainder of 2011 and 2012. The maturity of the Term Loan on December 21, 2011 will be funded with available cash and borrowings from the Revolving Facility. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings. As of September 30, 2011, \$320.9 million is outstanding under the Revolving Facility and \$82.0 million is outstanding under the Term Loan. The Term Loan is classified within the current portion of long-term debt on the Consolidated Balance Sheet.

**Item 3. *Quantitative and Qualitative Disclosures About Market Risk.***

The Company is subject to market risk associated with changes in foreign currency exchange rates and interest rates. The Company may, from time to time, enter into foreign currency forward contracts and interest rate swaps on its debt when it believes there is a financial advantage in doing so. A treasury risk management policy, adopted by the Board of Directors, describes the procedures and controls over derivative financial and commodity instruments, including foreign currency forward contracts and interest rate swaps. Under the policy, the Company does not use derivative financial or commodity instruments for trading purposes, and the use of these instruments is subject to strict approvals by senior officers. Typically, the use of derivative instruments is limited to foreign currency forward contracts and interest rate swaps on the Company's outstanding long-term

---

**Table of Contents**

debt. The Company's exposure related to derivative instruments primarily relates to the forward setting interest rate contract, where a 25-basis point movement in the ten year U.S. treasury yield would result in an approximate \$8.2 million change in the value of the forward setting interest rate contract.

The Company's foreign currency exchange rate risk is limited principally to the Euro, British Pound, Canadian Dollar and Chinese Renminbi. The Company manages its foreign exchange risk principally through invoicing customers in the same currency as the source of products. The effect of transaction gains and losses is reported within other income (expense)-net on the Consolidated Statements of Operations.

The Company's interest rate exposure is primarily related to the \$818.6 million of total debt outstanding at September 30, 2011. Approximately 40% of the debt is priced at interest rates that float with the market. A 50 basis point movement in the interest rate on the floating rate debt would result in an approximate \$1.6 million annualized increase or decrease in interest expense and cash flows. The remaining debt is fixed rate debt.

**Item 4. *Controls and Procedures.***

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by Rule 13a-15(b) promulgated under the Securities Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and the Company's Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company's Chief Executive Officer and Chief Financial Officer concluded as of September 30, 2011, that the Company's disclosure controls and procedures were effective.

There has been no change in the Company's internal controls over financial reporting during the Company's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal controls over financial reporting.

**PART II. OTHER INFORMATION**

**Item 1. *Legal Proceedings.***

The Company and six of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. Such components were acquired from third party suppliers, and were not manufactured by any of the subsidiaries. To date, the majority of the Company's settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover such settlements and legal costs, or how insurers may respond to claims that are tendered to them. Claims have been filed in jurisdictions throughout the United States. Most of the claims resolved to date have been dismissed without payment. The balance have been settled for various insignificant amounts. Only one case has been tried, resulting in a verdict for the Company's business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company's business, financial position, results of operations or cash flow.

**Table of Contents**

The Company is also party to various other legal proceedings arising in the ordinary course of business, none of which is expected to have a material adverse effect on its business, financial condition, results of operations or cash flow.

**Item 2. *Unregistered Sales of Equity Securities and Use of Proceeds.***

| <b>Period</b>                           | <b>Total Number of<br/>Shares<br/>Purchased</b> | <b>Average Price<br/>Paid per<br/>Share</b> | <b>Total Number of<br/>Shares<br/>Purchased as<br/>Part of<br/>Publicly<br/>Announced<br/>Plans<br/>or<br/>Programs<sup>(1)</sup></b> | <b>Maximum Dollar<br/>Value that<br/>May Yet<br/>be Purchased<br/>Under the Plans<br/>or Programs<sup>(1)</sup></b> |
|---|---|---|---|---|
| July 1, 2011 to July 31, 2011           |   |   |   | \$ 75,000,020   |
| August 1, 2011 to August 31, 2011       |   |   |   | \$ 75,000,020   |
| September 1, 2011 to September 30, 2011 |   |   |   | \$ 75,000,020   |
| Total                                   |   |   |   | \$ 75,000,020   |

(1) On April 21, 2008, IDEX's Board of Directors authorized the repurchase of up to \$125.0 million of its outstanding common shares either in the open market or through private transactions.

**Item 6. *Exhibits.***

The exhibits listed in the accompanying Exhibit Index are filed or furnished as part of this report.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

IDEX Corporation

By: /s/ HEATH A. MITTS

Heath A. Mitts

*Vice President and Chief Financial Officer*

*(Principal Financial Officer)*

By: /s/ MICHAEL J. YATES

Michael J. Yates

*Vice President and Chief Accounting Officer*

*(Principal Accounting Officer)*

October 31, 2011

**Table of Contents****EXHIBIT INDEX**

| <b>Exhibit</b> |   |
|----------------|---|
| <b>Number</b>  | <b>Description</b>  |
| 3.1            | Restated Certificate of Incorporation of IDEX Corporation (formerly HI, Inc.) (incorporated by reference to Exhibit No. 3.1 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on April 21, 1988)   |
| 3.1(a)         | Amendment to Restated Certificate of Incorporation of IDEX Corporation (formerly HI, Inc.), (incorporated by reference to Exhibit No. 3.1(a) to the Quarterly Report of IDEX on Form 10-Q for the quarter ended March 31, 1996, Commission File No. 1-10235)  |
| 3.1(b)         | Amendment to Restated Certificate of Incorporation of IDEX Corporation (incorporated by reference to Exhibit No. 3.1(b) to the Current Report of IDEX on Form 8-K dated March 24, 2005, Commission File No. 1-10235)  |
| 3.2            | Amended and Restated By-Laws of IDEX Corporation (incorporated by reference to Exhibit No. 3.2 to Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on July 17, 1989)   |
| 3.2(a)         | Amended and Restated Article III, Section 13 of the Amended and Restated By-Laws of IDEX Corporation (incorporated by reference to Exhibit No. 3.2(a) to Post-Effective Amendment No. 3 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on February 12, 1990)  |
| 4.1            | Restated Certificate of Incorporation and By-Laws of IDEX Corporation (filed as Exhibits No. 3.1 through 3.2(a))  |
| 4.2            | Specimen Certificate of Common Stock of IDEX Corporation (incorporated by reference to Exhibit No. 4.3 to the Registration Statement on Form S-2 of IDEX, et al., Registration No. 33-42208, as filed on September 16, 1991)  |
| *31.1          | Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002  |
| *31.2          | Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002  |
| *32.1          | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350   |
| *32.2          | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350   |
| *101           | The following financial information from IDEX Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, formatted in XBRL includes: (i) Condensed Consolidated Income Statements for the fiscal periods ended September 30, 2011 and September 30, 2010, (ii) Condensed Consolidated Balance Sheets at September 30, 2011 and December 31, 2010, (iii) Condensed Consolidated Cash Flow Statements for the fiscal periods ended September 30, 2011 and September 30, 2010, and (iv) the Notes to the Condensed Consolidated Financial Statements. |

\* Filed herewith